TP1021

TP1021 is a small molecule drug candidate developed by Tetra Pharm Technologies, currently in Phase 1 clinical development for the treatment of obesity and appetite stimulation. The drug is designed to modulate the endocannabinoid system (ECS), a complex cell-signaling system that plays a crucial role in regulating energy balance, metabolism, and appetite. Tetra Pharm Technologies specializes in cannabinoid-based therapeutics and utilizes proprietary formulation technologies to enhance the bioavailability and delivery of these compounds. TP1021 represents the company's expansion into metabolic diseases, aiming to leverage the therapeutic potential of cannabinoid receptor modulation to address conditions characterized by dysregulated appetite and metabolic dysfunction.